CD4 and cancer: Dysfunctional EZH2 is associated with the development of multiple cancer types in humans and can promote immune evasion by inhibiting intra-tumoral antigen presentation, immune cell migration, and enhancing CD4+ T regulatory cell (Treg) suppressive activity (Kang et al., 2020; Kim et al., 2020).